BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15042533)

  • 1. Clearing minimal residual disease with rituximab consolidation therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearing Minimal Residual Disease with Rituximab Consolidation Therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31 Suppl 2():33-37. PubMed ID: 28140108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes in transplantation.
    Brugger W
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):23-6. PubMed ID: 12040531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.
    Mangel J; Buckstein R; Imrie K; Spaner D; Franssen E; Pavlin P; Boudreau A; Pennell N; Combs D; Berinstein NL
    Ann Oncol; 2003 May; 14(5):758-65. PubMed ID: 12702531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
    Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
    Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Gisselbrecht C; Mounier N
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):28-33. PubMed ID: 12652462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
    Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
    Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
    Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
    Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Lin TS; Copelan EA
    Curr Hematol Rep; 2003 Jul; 2(4):310-5. PubMed ID: 12901328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
    Pettengell R
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.